@inproceedings{inproceedings, title  = {{CLINICAL FRACTURE INCIDENCE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) AND RISK-REDUCTION FOLLOWING ADDITION OF ZOLEDRONIC ACID TO ANDROGEN DEPRIVATION THERAPY (ADT) WITH OR WITHOUT DOCETAXEL (DOC): LONG-TERM RESULTS FROM 2 PHASE 3 TRIALS FROM THE STAMPEDE PLATFORM PROTOCOL}},

 url = {{}},

 year = {{2023}},

 month = {{1}},

 author = {{Jones C and Sachdeva A and Murphy L and Murray M and Brown L and McCloskey E and Brown J and Attard G and Parmar M and James N and Sydes M et al}},

 volume = {{209}},

 journal = {{JOURNAL OF UROLOGY}},

 pages = {{E129-E129}},

 note = {{Accessed on 2025/03/10}}}